Lexicon announces post-hoc analysis of clinical data presented at ESC

Lexicon (LXRX) Pharmaceuticals announced that a post-hoc analysis of clinical data was presented Sunday, August 31, during an oral presentation at the European Society of Cardiology, ESC, 2025 Congress in Madrid, Spain. It is well-established that the incidence of stroke and myocardial infarction, known collectively as major cardiovascular adverse events, rises with age, as does incidence of heart failure events. Sotagliflozin, a dual sodium-glucose cotransport 1 and 2 inhibitor, was approved by the FDA based on its demonstrated efficacy in improving HF endpoints in patients with chronic kidney disease or HF. This latest Lexicon-funded analysis examined how the efficacy of sotagliflozin varies with age, particularly among older adults, and used data pooled from the two previous pivotal Phase 3 studies of sotagliflozin, SCORED and SOLOIST-WHF. The robust data set included nearly 12,000 participants, about 70% of whom were 65 or older. This age group represents a very large population in which type 2 diabetes, CKD and/or worsening HF are relatively common. Patients were evaluated by age, both categorically and continuously. The primary endpoint was total cardiovascular death, hospitalization for HF, or urgent visit for HF. Additional endpoints included total MACE. Sotagliflozin demonstrated a consistent reduction in both endpoints, as compared to placebo across the spectrum of age.